| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| G Perrault, R Depoortere, E Morel, D J Sanger, B Scatto. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. The Journal of pharmacology and experimental therapeutics. vol 280. issue 1. 1997-02-10. PMID:8996184. |
this pharmacological profile of amisulpride, characterized by a preferential blockade of effects involving presynaptic mechanisms and limbic structures, may explain the clinical efficacy of this drug against both negative and positive symptoms of schizophrenia and its low propensity to produce extrapyramidal side effects. |
1997-02-10 |
2023-08-12 |
mouse |
| H Schoemaker, Y Claustre, D Fage, L Rouquier, K Chergui, O Curet, A Oblin, F Gonon, C Carter, J Benavides, B Scatto. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. The Journal of pharmacology and experimental therapeutics. vol 280. issue 1. 1997-02-10. PMID:8996185. |
this atypical profile may explain the therapeutic efficacy of amisulpride in the treatment of both positive and negative symptoms of schizophrenia. |
1997-02-10 |
2023-08-12 |
human |
| J L Martinot, M L Paillère-Martinot, M F Poirier, M H Dao-Castellana, C Loc'h, B Mazièr. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology. vol 124. issue 1-2. 1997-01-29. PMID:8935811. |
in vivo characteristics of dopamine d2 receptor occupancy by amisulpride in schizophrenia. |
1997-01-29 |
2023-08-12 |
Not clear |
| G Perrault, H Schoemaker, B Scatto. [The place of amisulpride in the atypical neuroleptic class]. L'Encephale. vol 22 Spec No 2. 1996-10-16. PMID:8767034. |
the enhancement of da function produced by its selective presynaptic receptor da blockade may account for the clinical efficacy of amisulpride against negative symptoms of schizophrenia. |
1996-10-16 |
2023-08-12 |
human |
| H Chabrol, D Bonnet, B Rog. [Psychopharmacology of autism]. L'Encephale. vol 22. issue 3. 1996-10-16. PMID:8767048. |
low doses of amisulpride which have been shown to improve negative symptoms in schizophrenia and serotoninergic antidepressants, which have proven effective in repetitive and ritualized behaviors, have recently began to be evaluated in controlled studies. |
1996-10-16 |
2023-08-12 |
Not clear |
| b' A P\\xc3\\xa9lissolo, M O Krebs, J P Oli\\xc3\\xa. [Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature]. L\'Encephale. vol 22. issue 3. 1996-10-16. PMID:8767050.' |
[treatment of negative symptoms in schizophrenia by amisulpride. |
1996-10-16 |
2023-08-12 |
human |
| b' A P\\xc3\\xa9lissolo, M O Krebs, J P Oli\\xc3\\xa. [Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature]. L\'Encephale. vol 22. issue 3. 1996-10-16. PMID:8767050.' |
three recent double-blind placebo controlled studies have suggested an efficacy of low doses (50-300 mg/day) of amisulpride in deficit forms of schizophrenia. |
1996-10-16 |
2023-08-12 |
human |
| P Boyer, Y Lecrubier, A J Puech, J Dewailly, F Aubi. Treatment of negative symptoms in schizophrenia with amisulpride. The British journal of psychiatry : the journal of mental science. vol 166. issue 1. 1995-04-26. PMID:7894879. |
treatment of negative symptoms in schizophrenia with amisulpride. |
1995-04-26 |
2023-08-12 |
Not clear |
| P Boyer, Y Lecrubier, A J Puech, J Dewailly, F Aubi. Treatment of negative symptoms in schizophrenia with amisulpride. The British journal of psychiatry : the journal of mental science. vol 166. issue 1. 1995-04-26. PMID:7894879. |
this study assessed the efficacy of amisulpride, a benzamide which increases dopaminergic transmission at low doses via presynaptic dopamine receptor blockade, on negative symptoms of schizophrenia. |
1995-04-26 |
2023-08-12 |
Not clear |
| b' G Allouche, R Joober, J M Vanelle, T Brochier, J P Oli\\xc3\\xa. [Sequence in prescribing neuroleptics: a therapeutic alternative in refractory schizophrenia?]. L\'Encephale. vol 20. issue 6. 1995-04-04. PMID:7875112.' |
authors report a case of schizophrenia which resists several neuroleptic trials (including haloperidol, chlorpromazine and thioproperazine) and responds to a sequence of clz and amisulpride. |
1995-04-04 |
2023-08-12 |
Not clear |
| b' G Allouche, R Joober, J M Vanelle, T Brochier, J P Oli\\xc3\\xa. [Sequence in prescribing neuroleptics: a therapeutic alternative in refractory schizophrenia?]. L\'Encephale. vol 20. issue 6. 1995-04-04. PMID:7875112.' |
the same model may be applied and the clozapine-amisulpride sequence is proposed as an alternative treatment in resistant schizophrenia: even if clz is uneffective, it may produce carryover effects which ease the action of amisulpride. |
1995-04-04 |
2023-08-12 |
Not clear |
| B Saletu, B Küfferle, J Grünberger, P Földes, A Topitz, P Andere. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. Neuropsychobiology. vol 29. issue 3. 1994-08-04. PMID:7912819. |
clinical, eeg mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. |
1994-08-04 |
2023-08-12 |
Not clear |
| B Saletu, B Küfferle, J Grünberger, P Földes, A Topitz, P Andere. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. Neuropsychobiology. vol 29. issue 3. 1994-08-04. PMID:7912819. |
thus, a double-blind, clinical, psychometric and neurophysiological study was carried out in 40 hospitalized patients with unproductive schizophrenia (mean age: 31 years; icd diagnoses: 295.0, 295.1 and 295.6) who were treated randomly either with the benzamide amisulpride (ami; n = 19) or low doses of fluphenazine (flu; n = 21). |
1994-08-04 |
2023-08-12 |
Not clear |
| D Widlöcher, J F Allilaire, A Guérard des Lauriers, Y Lecrubie. [Amisulpride, neuroleptic and antinegative action]. L'Encephale. vol 16. issue 2. 1990-07-18. PMID:1972055. |
high amisulpride doses, antidopaminergic, inhibit, in animals, the hyperdopaminergic symptomatology considered equivalent to positive schizophrenia, whereas low doses, dopamine-releasing and activating, improve hypodopaminergic symptomatology of negative schizophrenia. |
1990-07-18 |
2023-08-11 |
Not clear |
| D Widlöcher, J F Allilaire, A Guérard des Lauriers, Y Lecrubie. [Amisulpride, neuroleptic and antinegative action]. L'Encephale. vol 16. issue 2. 1990-07-18. PMID:1972055. |
in patients with negative schizophrenia (4 open and 3 double-blind studies) the effective dosage of amisulpride (solian 50) is about 150 mg/day, doses above 300 mg being ineffective or aggravating. |
1990-07-18 |
2023-08-11 |
Not clear |
| P Boye. [Efficacy of low doses of atypical neuroleptics (benzamides) in defect states]. Annales medico-psychologiques. vol 144. issue 6. 1987-03-26. PMID:2880542. |
in order to test this bipolar hypothesis two independent controlled studies were set up using the same new benzamide compound (amisulpride) at different doses in the opposite forms of schizophrenia. |
1987-03-26 |
2023-08-11 |
Not clear |
| P Boye. [Efficacy of low doses of atypical neuroleptics (benzamides) in defect states]. Annales medico-psychologiques. vol 144. issue 6. 1987-03-26. PMID:2880542. |
according to the results of these studies there are evidences to sustain the assertion that amisulpride at low doses is efficient in negative symptoms of schizophrenia such as poverty of ideation, flattening of affect, inattention, asociality and that the same compound at high doses is also efficient in productive forms of schizophrenia. |
1987-03-26 |
2023-08-11 |
Not clear |